Electra nabs $183M for its rare disease drug ambitions

The San Francisco-area biotech has a therapy in mid-stage testing for secondary hemophagocytic lymphohistiocytosis, a rare inflammatory condition.

Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and ...
GEN - Genetic Engineering and Biotechnology News

Electra Pursues Rare Inflammatory Disease and More with $183M Financing

Electra Therapeutics has completed an oversubscribed $183 million Series C financing it said will fund a global pivotal trial of its lead pipeline candidate, a frontline treatment for secondary ...

EQT Co-Leads $183 Million Funding Round of U.S. Biotech Electra Therapeutics

STOCKHOLM--Swedish buyout group EQT co-led a $183 million series C financing round in U.S. biotechnology company Electra Therapeutics. The financing was co-led by Nextech, with participation from new ...

Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic ...
Clinical Trials Arena on MSN

Electra Therapeutics secures $183m to fund Phase II/III trial of ELA026

The pivotal study is in progress at research centres in Europe and the US, where participants dosing has started.